Er Dong Hua
Director/Board Member at Hua Medicine (Shanghai) Co., Ltd.
Profile
Er Dong Hua is currently a Director at Hua Medicine (Shanghai) Co., Ltd.
and a Partner at 6 Dimensions Capital since 2017.
He previously worked as a Partner at Frontline Bioventures.
Er Dong Hua active positions
| Companies | Position | Start |
|---|---|---|
6 Dimensions Capital
 6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017. | Private Equity Investor | 2017-05-17 |
Hua Medicine (Shanghai) Co., Ltd.
 Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Director/Board Member | - |
Former positions of Er Dong Hua
| Companies | Position | End |
|---|---|---|
| Frontline Bioventures | Director/Board Member | 2017-05-17 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
| Frontline Bioventures | Finance |
6 Dimensions Capital
6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017. | Finance |
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Health Technology |
- Stock Market
- Insiders
- Er Dong Hua